Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL

Inclusion Criteria:

PROCUREMENT:

1. Any patient regardless of sex, with a diagnosis of Hodgkin or non-Hodgkin lymphoma.
2. Life expectancy of 6 weeks or greater.
3. Hgb greater than or equal to 7.0
4. Patient and,or parent,guardian able to give informed consent.

TREATMENT:

1. Any patient regardless of sex, with a diagnosis of Hodgkin or non-Hodgkin lymphoma:

   Group A: Patients greater than or equal to 18 years old
   * with active disease:

     * in second or subsequent relapse.
     * in first relapse for indolent lymphoma after first-line therapy for relapse.
     * or first relapse if immunosuppressive chemotherapy contraindicated.
     * primary refractory disease or if persistent disease after first-line therapy of relapse.
   * or multiply relapsed patients in remission who are at a high risk of relapse.
   * or the lymphoma is a second malignancy e.g. a Richters transformation of CLL after failing front line therapy.

   OR

   Group B: Patients greater than or equal to 18 years old after autologous or syngeneic SCT (as adjuvant therapy).

   OR

   Group C: azacytidine plus multiTAA-T cells Patients greater than or equal to 18 years old
   * with active disease in:

     * second or subsequent relapse
     * first relapse for indolent lymphoma after first line therapy for relapse
     * first relapse if immunosuppressive chemotherapy contraindicated
   * with primary refractory disease or persistent disease after first line therapy of relapse
   * or lymphoma as a second malignancy e.g. a Richters transformation of CLL after failing front line therapy

   OR

   GROUP D: Patients less than 18 yrs old
   * with active disease in:

     * second or subsequent relapse
     * first relapse for indolent lymphoma after first line therapy for relapse
     * first relapse if immunosuppressive chemotherapy contraindicated
   * with primary refractory disease or persistent disease after first line therapy of relapse
   * with lymphoma as a second malignancy e.g. a Richters transformation of CLL after failing front line therapy
2. Life expectancy of 6 weeks or greater.
3. Pulse oximetry of more than 95 percent on room air in patients who previously received radiation therapy.
4. Karnofsky,Lansky score of 50 or greater.
5. Creatinine 2X or less of upper limit of normal for age.
6. Patients should have been off other investigational therapy for one month prior to entry in this study.
7. Patients should have been off conventional therapy for at least 1 week prior to entry in this study, including rituximab.
8. Patient and,or parent,guardian able to give informed consent.
9. Due to unknown effects of this therapy on a fetus, pregnant women are excluded from this research. The male partner should use a condom. Females of child-bearing potential should use of at least two forms of contraception unless female has had a hysterectomy or tubal ligation.
10. Bilirubin 2X or less of upper limit of normal, AST 3X or less than the upper limit of normal, and Hgb greater than or equal to 7.0

    GROUP C (aza) Only:
11. Platelets greater than 25,000

Exclusion Criteria:

PROCUREMENT:

1. Patients with severe intercurrent infection.
2. Patients with active HIV infection at time of procurement (can be pending at the time of blood draw).
3. Patients receiving systemic corticosteroids.

TREATMENT:

1. Patients with severe intercurrent infection.
2. Patients receiving systemic corticosteroids.
3. Pregnant breastfeeding.
4. Active viral infection with HIV or hepatitis type B or C. "Active" infection defined as infectious disease testing indicating that patient blood is reactive for Hep B, C and/or HIV and confirmed using PCR to measure viral load.

   GROUP C (aza) Only:
5. Abnormal coagulation parameters (PT greater than 15 seconds, PTT greater than 40 seconds, and/or INR greater than 1.5)
6. Significant active cardiac disease within the previous 6 months including:

   1. NYHA class 4 CHF
   2. Unstable angina
   3. Myocardial infarction
7. Known or suspected hypersensitivity to azacitidine or mannitol
8. Patients with advanced malignant hepatic tumors.